{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T13:33:39Z","timestamp":1781530419670,"version":"3.54.1"},"reference-count":72,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>The optimal blood pressure (BP) target for adults with type 2 diabetes (T2DM) remains a topic of debate. This systematic review and meta-analysis aimed to investigate the efficacy of intensive BP control strategies compared to standard or less intensive approaches in adults with T2DM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>We comprehensively searched databases for studies comparing intensive vs. less intensive BP targets in individuals with T2DM. In this study, the group with the most intensive target was compared to the group with the least intensive target. Also, studies were analyzed based on current guideline recommendations. Outcomes of interest included major adverse cardiovascular events (MACE), all-cause mortality, cardiovascular mortality, myocardial infarction (MI), stroke, heart failure, retinopathy, neuropathy, nephropathy, and end-stage renal disease. Risk ratios with 95% confidence intervals were calculated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>The meta-analysis included 21 studies (16 RCTs) with 290,907 participants (mean age 61.84 years, 55.03% male). Guideline-based analyses showed comparable clinical outcomes between groups with no significant differences. However, the most intensive targets vs. the least intensive targets revealed that the intensive BP control group experienced a significantly lower risk of MACE (RR\u2005=\u20050.75, 0.58; 0.98), nonfatal MI (RR\u2005=\u20050.61, 0.41; 0.91), nonfatal stroke (RR\u2005=\u20050.60, 0.39; 0.92), and total stroke (RR\u2005=\u20050.61, 0.39; 0.95). Other outcomes were similar between groups. Subgroup analysis of RCTs mirrored the overall findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>In adults with T2DM, intensive BP control reduces the risk of cardiovascular events, such as MACE, stroke, and MI. Additionally, it demonstrates comparable diabetes-related complications to less intensive or standard controls.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajh\/hpaf140","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T11:50:15Z","timestamp":1753271415000},"page":"48-62","source":"Crossref","is-referenced-by-count":2,"title":["Intensive Blood Pressure Control in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Cardiovascular and Microvascular Outcomes"],"prefix":"10.1093","volume":"39","author":[{"given":"Asma","family":"Mousavi","sequence":"first","affiliation":[{"name":"Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences , Tehran ,","place":["Iran"]},{"name":"School of Medicine, Tehran University of Medical Sciences , Tehran ,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shayan","family":"Shojaei","sequence":"additional","affiliation":[{"name":"Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences , Tehran ,","place":["Iran"]},{"name":"School of Medicine, Tehran University of Medical Sciences , Tehran ,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir Parsa","family":"Abhari","sequence":"additional","affiliation":[{"name":"Heart Failure Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences , Isfahan ,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Alireza","family":"Mirhosseini","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Center, School of Medicine, Shiraz University of Medical Sciences , Shiraz ,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasoul","family":"Ebrahimi","sequence":"additional","affiliation":[{"name":"School of Medicine, Shahid Beheshti University of Medical Sciences , Tehran ,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erta","family":"Rajabi","sequence":"additional","affiliation":[{"name":"School of Medicine, Tehran University of Medical Sciences , Tehran ,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mashood Ahmad","family":"Farooqi","sequence":"additional","affiliation":[{"name":"PGY-1 Internal Medicine Central Michigan University , Saginaw, Michigan ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirali","family":"Azizpour","sequence":"additional","affiliation":[{"name":"School of Medicine, Tehran University of Medical Sciences , Tehran ,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiva","family":"Armani Moghadam","sequence":"additional","affiliation":[{"name":"Heart Failure Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences , Isfahan ,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Kuno","sequence":"additional","affiliation":[{"name":"Cardiology Division, Massachusetts General Hospital, Harvard Medical School , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Harrison","sequence":"additional","affiliation":[{"name":"Internal Medicine, Midwestern University , Glendale, Arizona ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilbert","family":"Aronow","sequence":"additional","affiliation":[{"name":"Cardiology Division, Westchester Medical Center, New York Medical College , Valhalla, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul","family":"Waheed","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, Dignity Health Medical Group , Gilbert, Arizona ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosy","family":"Thachil","sequence":"additional","affiliation":[{"name":"Elmhurst Hospital Center\/Mount Sinai School of Medicine , Elmhurst, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5676-3099","authenticated-orcid":false,"given":"Kaveh","family":"Hosseini","sequence":"additional","affiliation":[{"name":"Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences , Tehran ,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,25]]},"reference":[{"key":"2026011413221987000_CIT0001","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1016\/S0140-6736(24)00685-8","article-title":"Burden of disease scenarios for 204 countries and territories, 2022\u20132050: a forecasting analysis for the Global Burden of Disease Study 2021","volume":"403","author":"GBD 2021 Forecasting Collaborators","year":"2024","journal-title":"Lancet"},{"key":"2026011413221987000_CIT0002","doi-asserted-by":"publisher","first-page":"103758","DOI":"10.1016\/j.amsu.2022.103758","article-title":"Prevalence of hypertension in Type-2 diabetes mellitus","volume":"78","author":"Naseri","year":"2022","journal-title":"Ann Med Surg"},{"key":"2026011413221987000_CIT0003","doi-asserted-by":"publisher","first-page":"101422","DOI":"10.37349\/eemd.2025.101422","article-title":"A brief approach to hypertension in type 2 diabetes mellitus","volume":"2","author":"Gunes","year":"2025","journal-title":"Explor Endocrine Metab Dis"},{"key":"2026011413221987000_CIT0004","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.pcd.2020.11.001","article-title":"Characteristics of patients with hypertension in a population with type 2 diabetes mellitus. Results from the Turkish Nationwide SurvEy of Glycemic and Other Metabolic Parameters of Patients with Diabetes Mellitus (TEMD Hypertension Study)","volume":"15","author":"Sabuncu","year":"2021","journal-title":"Prim Care Diabetes"},{"key":"2026011413221987000_CIT0005","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1136\/heartjnl-2024-323998","article-title":"Blood pressure management in type 2 diabetes: a review of recent evidence","volume":"110","author":"Wamil","year":"2024","journal-title":"Heart"},{"key":"2026011413221987000_CIT0006","doi-asserted-by":"publisher","first-page":"17","DOI":"10.36011\/cpp.2024.6.e3","article-title":"Recent evidence on target blood pressure in patients with hypertension","volume":"6","author":"Kim","year":"2024","journal-title":"Cardiovasc Prev Pharmacother"},{"key":"2026011413221987000_CIT0007","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"key":"2026011413221987000_CIT0008","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/S0140-6736(07)61303-8","article-title":"Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial","volume":"370","author":"Patel","year":"2007","journal-title":"Lancet"},{"key":"2026011413221987000_CIT0009","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","article-title":"Effects of intensive blood-pressure control in type 2 diabetes mellitus","volume":"362","author":"Cushman","year":"2010","journal-title":"N Engl J Med"},{"key":"2026011413221987000_CIT0010","doi-asserted-by":"publisher","article-title":"Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. (0085-2538 (Print))","author":"Schrier","DOI":"10.1046\/j.1523-1755.2002.00213.x"},{"key":"2026011413221987000_CIT0011","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1056\/NEJMoa2412006","article-title":"Intensive blood-pressure","volume":"392","author":"Bi","year":"2025","journal-title":"N Engl J Med"},{"key":"2026011413221987000_CIT0012","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume-title":"Hypertension","author":"Whelton","year":"2018"},{"key":"2026011413221987000_CIT0013","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC Guidelines for the management of elevated blood pressure and hypertension","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur Heart J"},{"key":"2026011413221987000_CIT0014","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","article-title":"2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA)","volume":"41","author":"Mancia","year":"2023","journal-title":"J Hypertens"},{"key":"2026011413221987000_CIT0015","doi-asserted-by":"publisher","first-page":"S207","DOI":"10.2337\/dc25-S010","article-title":"10. Cardiovascular disease and risk management: standards of care in diabetes\u20142025","volume":"48","author":"Committee ADAPP","year":"2024","journal-title":"Diabetes Care"},{"key":"2026011413221987000_CIT0016","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026011413221987000_CIT0017","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1080\/02763869.2019.1588072","article-title":"PROSPERO: an international register of systematic review protocols","volume":"38","author":"Schiavo","year":"2019","journal-title":"Med Ref Serv Q"},{"key":"2026011413221987000_CIT0018","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"2026011413221987000_CIT0019","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"2026011413221987000_CIT0020","article-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","author":"Wells","year":"2000"},{"key":"2026011413221987000_CIT0021","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"2026011413221987000_CIT0022","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"2026011413221987000_CIT0023","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"key":"2026011413221987000_CIT0024","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J Stat Softw"},{"key":"2026011413221987000_CIT0025","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s40885-024-00280-x","article-title":"Blood pressure control in diabetic kidney disease: a post-hoc analysis of the FANTASTIC trial","volume":"30","author":"Park","year":"2024","journal-title":"Clin Hypertens"},{"key":"2026011413221987000_CIT0026","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1161\/HYPERTENSIONAHA.118.12414","article-title":"Effects of blood pressure lowering on clinical outcomes according to baseline blood pressure and cardiovascular risk in patients with type 2 diabetes mellitus","volume":"73","author":"Rahman","year":"2019","journal-title":"Hypertension"},{"key":"2026011413221987000_CIT0027","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1111\/dom.13248","article-title":"Effect of intensive blood pressure control in patients with type 2 diabetes mellitus over 9 years of follow-up: a subgroup analysis of high-risk ACCORDION trial participants","volume":"20","author":"Buckley","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"2026011413221987000_CIT0028","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1053\/j.ajkd.2018.07.016","article-title":"Effect of intensive blood pressure lowering on kidney tubule injury: findings from the ACCORD trial study participants","volume":"73","author":"Nadkarni","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"2026011413221987000_CIT0029","doi-asserted-by":"publisher","first-page":"e009114","DOI":"10.1161\/JAHA.118.009114","article-title":"Average clinician-measured blood pressures and cardiovascular outcomes in patients with type 2 diabetes mellitus and ischemic heart disease in the EXAMINE Trial","volume":"7","author":"White","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"2026011413221987000_CIT0030","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.2337\/dc16-0024","article-title":"Persistent effects of intensive glycemic control on retinopathy in type 2 diabetes in the action to control cardiovascular risk in diabetes (ACCORD) follow-on study","volume":"39","author":"Gotto","year":"2016","journal-title":"Diabetes Care"},{"key":"2026011413221987000_CIT0031","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.2337\/dc13-2334","article-title":"Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial","volume":"37","author":"Margolis","year":"2014","journal-title":"Diabetes Care"},{"key":"2026011413221987000_CIT0032","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/ki.2011.415","article-title":"Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients","volume":"81","author":"Ismail-Beigi","year":"2012","journal-title":"Kidney Int"},{"key":"2026011413221987000_CIT0033","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1001\/jama.2010.884","article-title":"Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease","volume":"304","author":"Cooper-DeHoff","year":"2010","journal-title":"JAMA"},{"key":"2026011413221987000_CIT0034","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","article-title":"Effects of intensive blood-pressure control in type 2 diabetes mellitus","volume":"362","author":"Cushman","year":"2010","journal-title":"N Engl J Med"},{"key":"2026011413221987000_CIT0035","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1056\/NEJMoa0806359","article-title":"Long-term follow-up after tight control of blood pressure in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"key":"2026011413221987000_CIT0036","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1681\/ASN.2004090763","article-title":"Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial","volume":"16","author":"Berl","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"2026011413221987000_CIT0037","first-page":"B54","article-title":"Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes","volume":"23","author":"Estacio","year":"2000","journal-title":"Diabetes Care"},{"key":"2026011413221987000_CIT0038","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/s0140-6736(98)04311-6","article-title":"Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group","volume":"351","author":"Hansson","year":"1998","journal-title":"Lancet"},{"key":"2026011413221987000_CIT0039","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","article-title":"Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group","volume":"317","author":"Turner","year":"1998","journal-title":"BMJ"},{"key":"2026011413221987000_CIT0040","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1161\/HYPERTENSIONAHA.122.20489","article-title":"Systolic blood pressure and cardiovascular risk in patients with diabetes: a prospective cohort study","volume":"80","author":"Rao","year":"2023","journal-title":"Hypertension"},{"key":"2026011413221987000_CIT0041","doi-asserted-by":"publisher","first-page":"i4070","DOI":"10.1136\/bmj.i4070","article-title":"Blood pressure and complications in individuals with type 2 diabetes and no previous cardiovascular disease: national population based cohort study","volume":"354","author":"Adamsson Eryd","year":"2016","journal-title":"BMJ."},{"key":"2026011413221987000_CIT0042","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jash.2011.11.001","article-title":"The effects of blood pressure control levels on the renoprotection of type 2 diabetic patients without overt proteinuria","volume":"6","author":"Uzu","year":"2012","journal-title":"J Am Soc Hypertens"},{"key":"2026011413221987000_CIT0043","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.jcjd.2020.10.002","article-title":"Glycated hemoglobin and blood pressure levels in adults with type 2 diabetes: how many patients are on target","volume":"45","author":"Bergonsi de Farias","year":"2021","journal-title":"Can J Diabetes"},{"key":"2026011413221987000_CIT0044","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1111\/jch.13675","article-title":"A nationwide assessment of blood pressure control and the associated factors in Chinese type 2 diabetes mellitus patients","volume":"21","author":"Zhang","year":"2019","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2026011413221987000_CIT0045","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1161\/HYPERTENSIONAHA.124.24173","article-title":"What is new and different in the 2024 European Society of Cardiology guidelines for the management of elevated blood pressure and hypertension","volume":"82","author":"McCarthy","year":"2025","journal-title":"Hypertension"},{"key":"2026011413221987000_CIT0046","doi-asserted-by":"publisher","first-page":"S207","DOI":"10.2337\/dc25-S010","article-title":"10. Cardiovascular disease and risk management: standards of care in diabetes\u20142025","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2024","journal-title":"Diabetes Care"},{"key":"2026011413221987000_CIT0047","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1056\/NEJMoa2111437","article-title":"Trial of intensive blood-pressure control in older patients with hypertension","volume":"385","author":"Zhang","year":"2021","journal-title":"N Engl J Med"},{"key":"2026011413221987000_CIT0048","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1161\/HYPERTENSIONAHA.118.11408","article-title":"Benefits of intensive blood pressure treatment in patients with type 2 diabetes mellitus receiving standard but not intensive glycemic control","volume":"72","author":"Tsujimoto","year":"2018","journal-title":"Hypertension"},{"key":"2026011413221987000_CIT0049","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0140-6736(24)01028-6","article-title":"Lowering systolic blood pressure to less than 120\u00a0mm Hg versus less than 140\u00a0mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial","volume":"404","author":"Liu","year":"2024","journal-title":"Lancet"},{"key":"2026011413221987000_CIT0050","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1001\/jamaneurol.2019.2167","article-title":"Effect of standard vs intensive blood pressure control on the risk of recurrent stroke: a randomized clinical trial and meta-analysis","volume":"76","author":"Kitagawa","year":"2019","journal-title":"JAMA Neurol"},{"key":"2026011413221987000_CIT0051","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1056\/NEJMoa1901281","article-title":"Final report of a trial of intensive versus standard blood-pressure control","volume":"384","author":"Lewis","year":"2021","journal-title":"N Engl J Med"},{"key":"2026011413221987000_CIT0052","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S2213-8587(22)00172-3","article-title":"Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis","volume":"10","author":"Nazarzadeh","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026011413221987000_CIT0053","doi-asserted-by":"publisher","first-page":"e0215362","DOI":"10.1371\/journal.pone.0215362","article-title":"Effects of intensive blood pressure lowering on mortality and cardiovascular and renal outcomes in type 2 diabetic patients: a meta-analysis","volume":"14","author":"Wang","year":"2019","journal-title":"PLoS One"},{"key":"2026011413221987000_CIT0054","doi-asserted-by":"publisher","first-page":"Cd008277CD008277","DOI":"10.1002\/14651858.CD008277.pub2","article-title":"Blood pressure targets for hypertension in people with diabetes mellitus","volume":"2013","author":"Arguedas","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"2026011413221987000_CIT0055","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S0140-6736(15)00805-3","article-title":"Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis","volume":"387","author":"Xie","year":"2016","journal-title":"Lancet"},{"key":"2026011413221987000_CIT0056","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1161\/HYPERTENSIONAHA.119.14240","article-title":"High blood pressure and cardiovascular disease","volume":"75","author":"Fuchs","year":"2020","journal-title":"Hypertension"},{"key":"2026011413221987000_CIT0057","doi-asserted-by":"publisher","first-page":"3567","DOI":"10.2147\/dmso.S319895","article-title":"A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives","volume":"14","author":"Reed","year":"2021","journal-title":"Diabetes Metab Syndr Obes"},{"key":"2026011413221987000_CIT0058","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","article-title":"Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study","volume":"321","author":"Stratton","year":"2000","journal-title":"BMJ"},{"key":"2026011413221987000_CIT0059","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41392-023-01400-z","article-title":"Diabetic vascular diseases: molecular mechanisms and therapeutic strategies","volume":"8","author":"Li","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"2026011413221987000_CIT0060","doi-asserted-by":"publisher","first-page":"96","DOI":"10.4236\/ym.2025.91009","article-title":"Micro and macrovascular complications in diabetes mellitus","volume":"09","author":"Mohammed","year":"2025","journal-title":"Yangtze Med"},{"key":"2026011413221987000_CIT0061","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1056\/NEJMoa021778","article-title":"Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes","volume":"348","author":"Gaede","year":"2003","journal-title":"N Engl J Med"},{"key":"2026011413221987000_CIT0062","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1161\/CIRCULATIONAHA.110.016337","article-title":"Blood pressure targets in subjects with type 2 diabetes mellitus\/impaired fasting glucose: observations from traditional and bayesian random-effects meta-analyses of randomized trials","volume":"123","author":"Bangalore","year":"2011","journal-title":"Circulation"},{"key":"2026011413221987000_CIT0063","doi-asserted-by":"publisher","first-page":"2864","DOI":"10.2337\/dc14-1296","article-title":"Diabetic kidney disease: a report from an ADA Consensus Conference","volume":"37","author":"Tuttle","year":"2014","journal-title":"Diabetes Care"},{"key":"2026011413221987000_CIT0064","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1093\/eurjpc\/zwad132","article-title":"The association of intensive blood pressure treatment and non-fatal cardiovascular or serious adverse events in older adults with mortality: mediation analysis in SPRINT","volume":"30","author":"Krishnaswami","year":"2023","journal-title":"Eur J Prev Cardiol"},{"key":"2026011413221987000_CIT0065","doi-asserted-by":"publisher","first-page":"S144","DOI":"10.2337\/dc22-S010","article-title":"Cardiovascular disease and risk management: standards of medical care in diabetes\u20142022","volume":"45","author":"Draznin","year":"2022","journal-title":"Diabetes Care"},{"key":"2026011413221987000_CIT0066","doi-asserted-by":"publisher","first-page":"S151","DOI":"10.2337\/dc21-S011","article-title":"11. Microvascular complications and foot care: standards of medical care in diabetes\u20142021","volume":"44","author":"Association AD","year":"2020","journal-title":"Diabetes Care"},{"key":"2026011413221987000_CIT0067","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1046\/j.1523-1755.2002.00213.x","article-title":"Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes","volume":"61","author":"Schrier","year":"2002","journal-title":"Kidney Int"},{"key":"2026011413221987000_CIT0068","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/hr.2008.34","article-title":"Relationship between the achieved blood pressure and the incidence of cardiovascular events in Japanese hypertensive patients with complications: a sub-analysis of the CASE-J trial","volume":"32","author":"Ogihara","year":"2009","journal-title":"Hypertens Res"},{"key":"2026011413221987000_CIT0069","doi-asserted-by":"publisher","first-page":"e009326","DOI":"10.1161\/JAHA.118.009326","article-title":"Effects of intensive systolic blood pressure lowering on cardiovascular events and mortality in patients with type 2 diabetes mellitus on standard glycemic control and in those without diabetes mellitus: reconciling results from ACCORD BP and SPRINT","volume":"7","author":"Beddhu","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"2026011413221987000_CIT0070","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.2337\/dc19-2047","article-title":"The influence of baseline diastolic blood pressure on the effects of intensive blood pressure lowering on cardiovascular outcomes and all-cause mortality in type 2 diabetes","volume":"43","author":"Ilkun","year":"2020","journal-title":"Diabetes Care"},{"key":"2026011413221987000_CIT0071","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s12933-019-0959-1","article-title":"Searching for optimal blood pressure targets in type 2 diabetic patients with coronary artery disease","volume":"18","author":"Shen","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"2026011413221987000_CIT0072","doi-asserted-by":"publisher","first-page":"593","DOI":"10.7326\/0003-4819-138-7-200304010-00018","article-title":"Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care","volume":"138","author":"Vijan","year":"2003","journal-title":"Ann Intern Med"}],"container-title":["American Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajh\/advance-article-pdf\/doi\/10.1093\/ajh\/hpaf140\/63857730\/hpaf140.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/39\/1\/48\/63857730\/hpaf140.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/39\/1\/48\/63857730\/hpaf140.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T18:22:22Z","timestamp":1768414942000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajh\/article\/39\/1\/48\/8214248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,25]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,7,25]]},"published-print":{"date-parts":[[2026,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ajh\/hpaf140","relation":{},"ISSN":["0895-7061","1941-7225"],"issn-type":[{"value":"0895-7061","type":"print"},{"value":"1941-7225","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,7,25]]}}}